Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) by Quarter
CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%) (%)
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel): 19.4% in Q3 2026, down 33.9 pts from a year earlier. That is the lowest of the 9 quarters on record here.
Where the Q3 2026 figure comes from
“|| US | 472 | 396 | 19.4 | 19.4 | —”
Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 19.4% | -33.9 pts | Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗ |
| Q2 2026 | Jun 28, 2026 | 31.7% | – | Form 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗ |
| Q1 2026 | Mar 29, 2026 | 36.2% | – | Form 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗ |
| Q4 2025 | Dec 28, 2025 | 38.2% | – | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| Q3 2025 | Sep 28, 2025 | 53.3% | -31.6 pts | Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗ |
| Q3 2024 | Sep 29, 2024 | 84.9% | – | Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗ |
| Q2 2024 | Jun 30, 2024 | 46.5% | – | Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗ |
| Q1 2024 | Mar 31, 2024 | 99.8% | +44.8 pts | Form 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗ |
| Q1 2023 | Apr 2, 2023 | 55.0% | – | Form 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-carvykti-us-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.